Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00425607 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria
A Phase 2 study of Progeria and Hutchinson-Gilford Syndrome, sponsored by Monica E. Kleinman.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT00425607: Completed Phase 2 study of Progeria and Hutchinson-Gilford Syndrome, sponsored by Monica E. Kleinman.
NCT00425607 is a Phase 2 study of Progeria and Hutchinson-Gilford Syndrome that has completed, run by Monica E. Kleinman. The registered enrollment target is 29 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00425607, a Phase 2 study of Progeria and Hutchinson-Gilford Syndrome, has completed, sponsored by Monica E. Kleinman.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label dose adjusted phase II trial of the oral farnesyltransferase inhibitor (FTI) lonafarnib (SCH66336) for patients with HGPS and progeroid laminopathies.
Primary Outcome
Activity was assessed by determining the change in rate of weight gain over two years from baseline (determined pre-therapy for each patient). Primary outcome success was predefined as a 50% increase over pre-therapy in estimated annual rate of weight gain, or change from pre-therapy weight loss to statistically significant on-study weight gain.
Conditions Studied
Interventions
- DRUG Lonafarnib
Study Locations (1)
Massachusetts
- Children's Hospital Boston - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
What the finished NCT00425607 record still lists
NCT00425607 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Progeria appearing as the primary indexed condition, and to 1 intervention - of which Lonafarnib is the first listed.
NCT00425607 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00425607 about?
NCT00425607 is a clinical study titled "Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria". This is an open label dose adjusted phase II trial of the oral farnesyltransferase inhibitor (FTI) lonafarnib (SCH66336) for patients with HGPS and progeroid laminopathies.
What is the current status of trial NCT00425607?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2007-05. Estimated completion is 2009-10.
What conditions does trial NCT00425607 study?
This clinical trial studies the following conditions: Progeria, Hutchinson-Gilford Syndrome.
What interventions are being tested in trial NCT00425607?
The interventions under investigation include: Lonafarnib (DRUG).
Who is sponsoring clinical trial NCT00425607?
This trial is sponsored by Monica E. Kleinman, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00425607 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00425607's enrollment target sits among peer trials
29 1669th of 2000 higher than 324 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia